ARV771 (also known as ARV-771) is a small molecule inhibitor used for the treatment of various types of cancer. In this article, we will explore the properties, uses, health benefits, potential effects, mechanism, safety, side effects, and dosing information of ARV771.
Introduction: ARV771 is a novel small molecule inhibitor that targets p53-MDM2 interaction, which plays a key role in cancer cell survival and proliferation. By disrupting this interaction, ARV771 has shown promise in preclinical studies as a cancer therapy.
Chemical name: The chemical name of ARV771 (ARV-771) is (R)-N-(6-chloro-5-methylpyridin-2-yl)-2-hydroxy-3-methoxybenzamide.
Molecular formula: The molecular formula of ARV771 is C16H15ClN2O3.
Formula weight: The formula weight of ARV771 is 326.75 g/mol.
CAS No: The CAS number for ARV771 (ARV-771) is 1949837-12-0.
Top ten keywords from Google and Synonyms:
Health benefits of ARV771: As a potential cancer therapy, ARV771 has the potential to provide significant health benefits to patients suffering from various types of cancer. By disrupting the p53-MDM2 interaction, this compound may be able to promote tumor regression and improve patient outcomes.
Potential effects: ARV771 has been shown to have potent anti-cancer activity in preclinical studies, with efficacy demonstrated against a range of cancer types, including breast cancer, lung cancer, and leukemia. The compound has also shown promise in combination with other cancer therapies, such as chemotherapy and radiation therapy.
Product mechanism: ARV771 acts by disrupting the interaction between p53 and MDM2, two proteins involved in regulating cell growth and survival. By blocking the binding of MDM2 to p53, the compound can activate the p53 tumor suppressor pathway and induce apoptosis in cancer cells.
Safety: As with any new drug candidate, the safety of ARV771 is still being evaluated in preclinical and clinical studies. However, early results suggest that the compound is generally well-tolerated, with manageable toxicity profiles. Ongoing studies will continue to monitor the safety of this compound.
Side effects: As with all drugs, there is the potential for side effects when using ARV771. Some potential side effects include diarrhea, fatigue, nausea, vomiting, and decreased appetite. More serious side effects may occur in some patients, and these should be monitored closely by healthcare professionals.
Dosing information: The optimal dosing regimen for ARV771 is still being determined in clinical trials. However, early studies suggest that the compound is most effective when administered orally once daily, with dosages ranging from 50-300 mg per day. Dosing should always be determined by a healthcare professional and based on the individual needs of the patient.
Conclusion: ARV771 (ARV-771) represents a promising new cancer therapy that disrupts the p53-MDM2 interaction to promote tumor regression and improve patient outcomes. While the compound is still in the early stages of development, preclinical studies suggest that it has potent anti-cancer activity and manageable toxicity profiles. Ongoing clinical trials will help determine the optimal dose and safety profile of this compound, paving the way for its eventual use in cancer treatment.
